^
Association details:
| Biomarker: | ERBB4 G1109C |
|---|---|
| Cancer: | Esophageal Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC
Excerpt:
Two cell lines, KYSE270 and SAS, were hypersensitive to afatinib (Fig. 1A and B). In contrast, none of the cell lines were sensitive to cetuximab or erlotinib….KYSE270 cell lines harbored an EGFR L861Q mutation and that the SAS cell line harbored an HER4 G1109C mutation, respectively...
DOI:
10.1158/1535-7163.MCT-15-0737
